ESTROGEN PREVENTION TRIAL

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项由国家老龄化研究所支持的随机、安慰剂对照、预防型临床试验，为期四年，其中有痴呆症阳性家族史的65岁及以上女性给予倍美力/普美宝（基于子宫状态）与安慰剂，以预防家族史脆弱人群中阿尔茨海默病的发生。 我们目前在试验中招募了28名女性，我们仍在积极招募。 这项试验是由RO-1支持玛丽佐野博士，谁最近从哥伦比亚山。纽约的西奈半岛。 在竞争性更新现场访问期间，RO-1获得了159分，并相信资金将继续支持这项正在进行的工作。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, placebo-controlled, prevention-type clinical trial supported by the National Institute on Aging for a four-year period of exposure in which women 65 years and older who have a positive family history of dementia are given premarin/prempro (based on uterine status) versus placebo in an effort to prevent the occurence of Alzheimer's disease in a population that is vulnerable by family history. Our current enrollment in the trial is 28 women, and we are still actively enrolling. This trial is supported by an RO-1 to Dr. Mary Sano, who recently moved from Columbia to Mt. Sinai in New York. During the competitive renewal site visit, the RO-1 received a score of 159, and is confident that the funding will continue for another five years to support this ongoing work.